UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology

Meghan J. Price; Annee D. Nguyen; Jovita K. Byemerwa; Jasmine Flowers; César D. Baëta; C. Rory Goodwin

doi:10.18632/oncotarget.28514

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology

Meghan J. Price, Annee D. Nguyen, Jovita K. Byemerwa, Jasmine Flowers, César D. Baëta and C. Rory Goodwin _

PDF | Full Text | How to cite | Press Release

Oncotarget. 2023; 14:843-857. https://doi.org/10.18632/oncotarget.28514

Metrics: PDF 471 views | Full Text 1778 views | ?

Abstract

Meghan J. Price1, Annee D. Nguyen2, Jovita K. Byemerwa3, Jasmine Flowers4, César D. Baëta5 and C. Rory Goodwin6

1 Department of Internal Medicine, Johns Hopkins Hospital, Baltimore, MD 21287, USA

2 Department of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA

3 Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27708, USA

4 Department of Neurosurgery, Associated with Duke University Medical Center, Durham, NC 27710, USA

5 Department of Epidemiology and Clinical Research, Stanford University, Stanford, CA 94305, USA

6 Department of Neurosurgery, Duke Center for Brain and Spine Metastasis and Duke Cancer Institute, Durham, NC 27710, USA

Correspondence to:

C. Rory Goodwin,

email:

[email protected]

Keywords: UDP-6 glucose dehydrogenase; UGDH; cancer; oncology; cancer biology

Received: August 02, 2023 Accepted: September 04, 2023 Published: September 28, 2023

Copyright: © 2023 Price et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key reaction in hormone and xenobiotic metabolism and in the production of extracellular matrix precursors. In this review, we classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describe its involvement in key canonical cancer signaling pathways, and identify methods to inhibit UGDH, its substrates, and its downstream products. As such, we position UGDH as an enzyme to be exploited as a potential prognostication marker in oncology and a therapeutic target in cancer biology.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28514

Publication Alerts

Reviews:

UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology

Abstract